Favipiravir and COVID-19: A Simplified Summary

被引：62

作者：

Ghasemnejad-Berenji, Morteza ^{[1
]}

Pashapour, Sarvin ^{[2
]}

机构：

[1] Urmia Univ Med Sci, Dept Pharmacol & Toxicol, Fac Pharm, Orumiyeh, Iran

[2] Urmia Univ Med Sci, Motahari Hosp, Dept Pediat, Fac Med, Orumiyeh, Iran

来源：

DRUG RESEARCH | 2021年 / 71卷 / 03期

关键词：

antiviral drugs; drug research; clinical trials; IN-VIVO ACTIVITIES; CLINICAL CHARACTERISTICS; T-705; FAVIPIRAVIR; VIRUS; VITRO; WUHAN;

D O I：

10.1055/a-1296-7935

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan, China, at the end of 2019 and then spread rapidly all over the world. However, there are no specific antiviral therapies for COVID-19, using the agents which approved or in development for other viral infections is one of the potentially quickest ways to find treatment for this new viral infection. Favipiravir is an effective agent that acts as a nucleotide analog that selectively inhibits the viral RNA dependent RNA polymerase or causes lethal mutagenesis upon incorporation into the virus RNA. In view of recent studies and discussion on favipiravir, in this mini review we aimed to summarize the clinical trials studying the efficacy and safety of favipiravir in patients with COVID-19.

引用

页码：166 / 170

页数：5

共 29 条

[1] [Anonymous], 2014, AV FAV REV REP
[2] [Anonymous], 2020, Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China, DOI 10.1101/2020.02.13.20022673
[3] T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
Baranovich, Tatiana
Wong, Sook-San
Armstrong, Jianling
Marjuki, Henju
Webby, Richard J.
Webster, Robert G.
Govorkova, Elena A.
[J]. JOURNAL OF VIROLOGY, 2013, 87 (07) : 3741 - 3751
[4] RETRACTED: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study (Retracted Article)
Cai, Qingxian
Yang, Minghui
Liu, Dongjing
Chen, Jun
Shu, Dan
Xia, Junxia
Liao, Xuejiao
Gu, Yuanbo
Cai, Qiue
Yang, Yang
Shen, Chenguang
Li, Xiaohe
Peng, Ling
Huang, Deliang
Zhang, Jing
Zhang, Shurong
Wang, Fuxiang
Liu, Jiaye
Chen, Li
Chen, Shuyan
Wang, Zhaoqin
Zhang, Zheng
Cao, Ruiyuan
Zhong, Wu
Liu, Yingxia
Liu, Lei
[J]. ENGINEERING, 2020, 6 (10) : 1192 - 1198
[5] Chen C, 2020, MEDRXIV, DOI 10.1101/2020.03.17.20037432
[6] Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, Leen
Abdelnabi, Rana
Neyts, Johan
[J]. ANTIVIRAL RESEARCH, 2018, 153 : 85 - 94
[7] Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, Liying
Hu, Shasha
Gao, Jianjun
[J]. DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (01) : 58 - 60
[8] Mechanism of action of T-705 against influenza virus
Furuta, Y
Takahashi, K
Kuno-Maekawa, M
Sangawa, H
Uehara, S
Kozaki, K
Nomura, N
Egawa, H
Shiraki, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) : 981 - 986
[9] In vitro and in vivo activities of anti-influenza virus compound T-705
Furuta, Y
Takahashi, K
Fukuda, Y
Kuno, M
Kamiyama, T
Kozaki, K
Nomura, N
Egawa, H
Minami, S
Watanabe, Y
Narita, H
Shiraki, K
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 977 - 981
[10] Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
Furuta, Yousuke
Komeno, Takashi
Nakamura, Takaaki
[J]. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2017, 93 (07): : 449 - 463

← 1 2 3 →